National Health (Weighted average disclosure price main disclosure cycle) Amendment Determination 2013 (No. 1) (No. PB 18 of 2013) (Cth)

Case

PB 18 of 2013

National Health (Weighted average disclosure price – main disclosure cycle) Amendment Determination 2013 (No. 1)

National Health Act 1953

I, FELICTY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.

Dated     7 March 2013

FELICTY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

  1. Name of Determination

(1)     This Determination is the National Health (Weighted average disclosure price – main disclosure cycle) Amendment Determination 2013 (No. 1).

(2)     This Determination may also be cited as PB 18 of 2013.

  1. Commencement

This Determination commences on the day after it is registered.

3              Amendments to PB 107 of 2012

Schedule 1 amends the National Health (Weighted average disclosure price – main disclosure cycle) Determination 2012 (PB 107 of 2012).

Schedule 1             Amendments

[1]      Schedule 1

omit:

376 Hydroxocobalamin Injection 1 mg (as acetate) in 1 mL Injection Vita-B12

insert:

376 Hydroxocobalamin Injection 1 mg (as acetate) in 1 mL Injection Vita-B12 5.62

[2]      Schedule 2, After

253 Macrogol 3350 Sachets containing powder for oral solution 13.125 g with electrolytes, 30  Oral Movicol 11.38

insert:

   253A Macrogol 3350 Sachets containing powder for oral solution 17 g, 30  Oral MediHealth ClearLax 11.38

[3]      Schedule 2, After

306 Morphine Injection containing morphine sulphate 10 mg in 1 mL Injection Hospira Pty Limited 3.71

insert:

   306A Morphine Injection containing morphine sulphate 10 mg in 1 mL (with preservative) Injection Morphine Sulphate Workhardt 7.42

[4]      Schedule 2

omit:

365 Paraffin Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinyl palmitate, 5 g Application to the eye VitA-POS

insert:

365 Paraffin Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinyl palmitate, 5 g Application to the eye VitA-POS 5.99

Note

1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See

Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0